Efficacy and Safety of Elranatamab in Pts with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3

42 Views

07/14/23

Dr. Nizar Bahlis, University of Calgary, presents the results of the ongoing MagnetisMM-3 clinical trial looking at the effects of elranatamab in people with multiple myeloma whose cancer did not respond to treatment at all or came back after responding to previous treatment.

Background:

Elranatamab is a humanized bispecific antibody that targets both B-cell maturation antigen (BCMA)-expressing multiple myeloma (MM) cells and CD3-expressing T cells. MagnetisMM-3 (NCT04649359) is an open-label, multicenter, non-randomized, phase 2 study to evaluate the safety and efficacy of elranatamab monotherapy in patients (pts) with relapsed/refractory MM (RRMM). Results in pts with RRMM and no prior BCMA-targeted treatment (Cohort A) are presented.

Conclusions:

Results suggest that subcutaneous 76 mg QW elranatamab is efficacious and has a manageable safety profile in pts with triple-class- and penta-drug refractory MM and no prior BCMA-targeted treatment. These results support continued development of elranatamab for pts with MM.

Authors:

Nizar Jacques Bahlis, MD, Michael H. Tomasson, MD, Mohamad Mohty, MD PhD, Ruben Niesvizky, MD, Ajay K. Nooka, MD, MPH, FACP, Salomon Manier, MD, PhD, Christopher Maisel, MD, Yogesh Jethava, MD, Joaquin Martinez-Lopez, MD, PhD, H Miles Prince, MD, Bertrand Arnulf, Paula Rodriguez Otero, Guenther Koehne, MD, PhD, Cyrille Touzeau, Noopur Raje, MD, Shinsuke Iida, MD, PhD, Marc-Steffen Raab, Eric Leip, PhD, Sharon Sullivan, PhD, Umberto Conte, PharmD, Andrea Viqueira, MD and Alexander M Lesokhin, MD

ASH Abstract#159: https://ash.confex.com/ash/202....2/webprogram/Paper16

_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma | https://facebook.com/myeloma
Twitter: @IMFMyeloma | https://twitter.com/IMFmyeloma
Instagram: @imfmyeloma | https://www.instagram.com/imfmyeloma
LinkedIn: https://www.linkedin.com/compa....ny/international-mye

Support the IMF | Donate Now! https://secure.myeloma.org/page/40697/donate/1
Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.